Mehmet Ali Nahit Şendur (Mehmet A N Sendur, Mehmet An Sendur, Mehmet Ali Sendur)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Small Cell Lung Cancer

Top Venues

Oncology and therapy

Future oncology (London, England)

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

This page only lists publications with an associated author ORCID identifier.

Publications

Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom, Melina E Marmarelis, Rachel E Sanborn, James Chih-Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massuti, Alexander I Spira, Se-Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji-Youn Han, Mariam Alexander, Rohit Joshi, Enriqueta Felip Font, Pei-Jye Voon, Pongwut Danchaivijitr, Ping-Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K Sabari, Angel Qin, Dariusz Mirosław Kowalski, Mehmet Ali Nahit Şendur, John Xie, Debopriya Ghosh, Ali A Alhadab, Nahor Haddish-Berhane, Pamela L Clemens, Patricia Lorenzini, Remy B Verheijen, Mohamed Gamil, Joshua M Bauml, Mahadi Baig, Antonio Passaro, null null
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet Ali Nahit Şendur
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials. Oncology and therapy 12 (3) (2024)
Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet Ali Nahit Şendur
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials. Oncology and therapy 12 (3) (2024)
Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet Ali Nahit Şendur
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials. Oncology and therapy 12 (3) (2024)
Safa Can Efil, Sebnem Yucel, Furkan Ceylan, Hilal Karakaş, İrfan Karahan, Sema Nur Özsan, Hakan Kosku, Şebnem Yaman, Muhammed Bülent Akıncı, Didem Şener Dede, Bülent Yalçın, Mehmet Ali Nahit Şendur
A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet Ali Nahit Şendur
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials. Oncology and therapy (2024)
Natasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna R Minchom, Melina E Marmarelis, Rachel E Sanborn, James Chih-Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massuti, Alexander I Spira, Se-Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji-Youn Han, Mariam Alexander, Rohit Joshi, Enriqueta Felip Font, Pei-Jye Voon, Pongwut Danchaivijitr, Ping-Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K Sabari, Angel Qin, Dariusz Mirosław Kowalski, Mehmet Ali Nahit Şendur, John Xie, Debopriya Ghosh, Ali A Alhadab, Nahor Haddish-Berhane, Pamela L Clemens, Patricia Lorenzini, Remy B Verheijen, Mohamed Gamil, Joshua M Bauml, Mahadi Baig, Antonio Passaro, null null
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Mahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten, Hacı Mehmet Türk, Zuhat Urakci, Çağatay Arslan, Sinemis Çelik, Faysal Dane, Mehmet Ali Nahit Şendur, Cemil Bilir, Bülent Karabulut, Irfan Cicin, Erdem Cubukcu, Mustafa Karaca, Melike Ozcelik, Mustafa Yıldırım, Eda Tanrikulu, Ahmet Alacacioglu, Özgür Açıkgöz, Başak Öven, Çağlayan Geredeli, Timucin Çil, Hakan Harputluoğlu, Umut Kefeli, Oktay Bozkurt, Deniz Tural, Abdullah Sakin, Şuayip Yalçın, Mahmut Gumus
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Saadettin Kılıçkap, Sertac Ak, Oldac U Dursun, Mehmet Ali Nahit Şendur, Nuri Karadurmus, Umut Demirci
Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events. Future oncology (London, England) (2023)
Irfan Cicin, Nuri Karadurmus, Ahmet Bilici, Taha Bahsi, Mehmet Ali Nahit Şendur, Umut Demirci, Sema Sezgin Goksu, Ozlem Er, Serdar Ceylaner, Ozge Fulya Ozturk Saglam, Birkan Aver, Saadettin Kılıçkap
Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye. Future oncology (London, England) (2023)
Mustafa Gürbüz, Erman Akkuş, Abdullah Sakin, Semiha Urvay, Atike Gökçen Demiray, Suleyman Sahin, Teoman Sakalar, Cihan Erol, Mehmet Ali Nahit Şendur, Ahmet Bilgehan Şahin, Erdem Cubukcu, Deniz Can Guven, Saadettin Kılıçkap, Yakup Ergün, Doğan Uncu, Nazım Serdar Turhal, Necdet Üskent, Havva Yeşil Çinkir, Atakan Demir, Ramazan Acar, Nuri Karadurmus, Sema Türker, Mustafa Altınbaş, Mert Karaoğlan, Filiz Çay Şenler
Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group. Journal of gastrointestinal cancer (2021)